Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
- Details
- Category: Novartis
Novartis commemorates World CML Day by announcing the latest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy - a concept called treatment-free remission. More than 100 study sites are now enrolling patients to the trial program.
Bayer fights Chagas disease in Argentina together with Caritas
- Details
- Category: Bayer
The Bayer Cares Foundation and Caritas Argentina have laid the foundation for a new project to combat the Chagas disease in Argentina. Chagas disease is still an indication with a high unmet medical need because the minor, flu-like symptoms are rather non-specific and therefore often misinterpreted.
Christoph Franz nominated to become new Roche Chairman
- Details
- Category: Roche
At the forthcoming Annual Shareholders Meeting on 4 March 2014, the Roche Board of Directors will propose Christoph Franz to be elected as Chairman of the Board. Christoph Franz is thus nominated to succeed Franz B. Humer, who announced at the last shareholder meeting that he would not be standing for re-election.
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.
Novartis announces an exclusive global licensing and research collaboration with Regenerex
- Details
- Category: Novartis
Novartis today announced that it has entered into an exclusive global licensing and research collaboration agreement with Regenerex LLC, a biopharmaceutical company based in Louisville, Kentucky, for use of the company's novel Facilitating Cell Therapy (FCRx) platform. The hematopoietic stem cell-based FCRx platform has been investigated in kidney transplantation to induce stable immunological tolerance, resulting in graft survival without the need for lifelong immunosuppression.
Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announces new milestones for the novel oral anticoagulant Pradaxa® (dabigatran etexilate) with over two million patient-years of experience in all licensed indications globally.(1) In addition, the company confirms research currently underway for Pradaxa® in new cardiovascular patient populations, as well as robust plans to gather real-world evidence in patients with non-valvular atrial fibrillation (NVAF).
Onglyza® (saxagliptin) achieves primary safety endpoint in SAVOR cardiovascular outcomes trial
- Details
- Category: Bristol-Myers Squibb
AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events. In this study, Onglyza® (saxagliptin) met the primary safety objective, demonstrating no increased risk for the primary composite endpoint of cardiovascular death,
More Pharma News ...
- Novartis holds annual healthcare entrepreneur competition
- Nexavar® (sorafenib) granted priority review for differentiated thyroid cancer in the U.S.
- Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
- MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
- Novartis first company accredited with global CEO Cancer Gold Standard
- GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
- Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival